Morgan Stanley
DTIL icon

Morgan Stanley’s Precision BioSciences DTIL Stock Holding History

Morgan Stanley’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$673K Buy
122,277
+22,472
+23% +$104K ﹤0.01% 5332
2025
Q4 		$415K Buy
99,805
+89,331
+853% +$507K ﹤0.01% 5601
2025
Q3 		$57.8K Buy
10,474
+653
+7% +$3.13K ﹤0.01% 6355
2025
Q2 		$41.2K Sell
9,821
-2,450
-20% -$12.1K ﹤0.01% 6421
2025
Q1 		$58.5K Buy
12,271
+4,497
+58% +$22.9K ﹤0.01% 6216
2024
Q4 		$29.6K Sell
7,774
-2,760
-26% -$20.2K ﹤0.01% 6452
2024
Q3 		$94.4K Sell
10,534
-192
-2% -$1.85K ﹤0.01% 6030
2024
Q2 		$104K Sell
10,726
-1,033
-9% -$12.2K ﹤0.01% 5943
2024
Q1 		$159K Sell
11,759
-10,518
-47% -$129K ﹤0.01% 5801
2023
Q4 		$244K Buy
22,277
+14,613
+191% +$158K ﹤0.01% 5870
2023
Q3 		$78.5K Sell
7,664
-833
-10% -$12.8K ﹤0.01% 5990
2023
Q2 		$134K Buy
8,497
+1,095
+15% +$25K ﹤0.01% 5814
2023
Q1 		$167K Sell
7,402
-3,019
-29% -$99.5K ﹤0.01% 5790
2022
Q4 		$372K Sell
10,421
-8,569
-45% -$339K ﹤0.01% 5385
2022
Q3 		$740K Sell
18,990
-13,285
-41% -$631K ﹤0.01% 5061
2022
Q2 		$1.55M Buy
32,275
+20,253
+168% +$1.19M ﹤0.01% 4716
2022
Q1 		$1.11M Buy
12,022
+5,290
+79% +$719K ﹤0.01% 4914
2021
Q4 		$1.5M Sell
6,732
-5,801
-46% -$1.62M ﹤0.01% 4787
2021
Q3 		$4.34M Sell
12,533
-12,667
-50% -$4.29M ﹤0.01% 3891
2021
Q2 		$9.47M Buy
25,200
+7,255
+40% +$2.18M ﹤0.01% 3053
2021
Q1 		$5.57M Buy
17,945
+13,061
+267% +$4.57M ﹤0.01% 3294
2020
Q4 		$1.22M Buy
4,884
+920
+23% +$225K ﹤0.01% 4541
2020
Q3 		$732K Sell
3,964
-279
-7% -$55.5K ﹤0.01% 4426
2020
Q2 		$1.06M Buy
4,243
+355
+9% +$77.7K ﹤0.01% 4127
2020
Q1 		$704K Sell
3,888
-1,927
-33% -$504K ﹤0.01% 4181
2019
Q4 		$2.42M Buy
5,815
+5,676
+4,083% +$1.78M ﹤0.01% 3882
2019
Q3 		$35K Sell
139
-623
-82% -$203K ﹤0.01% 5845
2019
Q2 		$302K Buy
762
+759
+25,300% +$306K ﹤0.01% 4844
2019
Q1 		$2K Buy
+3
New +$1.59K ﹤0.01% 6451

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley's DTIL Position: Q1 2026 in Review

Morgan Stanley increased its Precision BioSciences (DTIL) stake by 23% in Q1 2026, buying an estimated $104K and bringing the position to 122,277 shares worth $673K. The position accounts for ﹤0.01% of the portfolio, ranked #5332.

Morgan Stanley first reported a position in DTIL in Q1 2019 and has held it in 29 quarters since. The position peaked at $9.47M in Q2 2021. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Morgan Stanley held 122,277 shares of Precision BioSciences worth $673K as of Q1 2026.
  • Morgan Stanley bought 22,472 Precision BioSciences shares in Q1 2026, an estimated $104K.
  • Precision BioSciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5332 holding.
  • Morgan Stanley first reported a position in Precision BioSciences in Q1 2019 and has held it in 29 quarters since.
  • Morgan Stanley's Precision BioSciences position peaked at $9.47M in Q2 2021.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.